Friday, 15 Dec 2017

You are here

Romosuzumab Followed by Alendronate is Best in Fracture Prevention

The NEJM reports that in high risk post-menopausal women, romosozumab for 12 months followed by alendronate resulted in a significantly lower fracture than alendronate alone. 

A randomized 24-month trial enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and treated them with either monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) for 12 months, followed by open-label alendronate. The primary endpoints were cumulative fracture incidence at 2 years.

In the end, the romosozumab-to-alendronate group had a 48% lower risk of new vertebral fractures (6.2%) than the alendronate-only group (11.9%).

Clinical fractures were also 27% lower risk with romosozumab (P<0.001).

The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group.

Hip fracture was lower by 38% in the romosozumab-to-alendronate group.

While adverse events were balanced between groups. there were slightly more adjudicated cardiovascular adverse events with romosozumab than with alendronate (2.5% vs.1.9%).

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Knee Surgery Outcomes Worse with Low Education

Reuters reports that patients who live in low-income communities and lack a college education may have worse pain after knee replacement surgery than their more educated neighbors, citing results from a recent study from the Hospital for Special Surgery in NY.

Weight Loss Does Not Protect OA Knees

A new study presented at the Radiological Society of North America (RSNA) shows that obese people with substantial weight loss may significantly slow down the rate of joint space narrowing (cartilage degeneration) in the knee cartilage, but only if they lose weight through diet and exercise or diet alone; excercise alone is insufficient. 

Prevalence of Arthritis Grossly Underestimated

Researchers at the Boston University School of Medicine have published a new report showing that arthritis affected 91 million adults in the US in 2015 or 37% of the poplulation. Their prevalence estimate is 68% higher than previously reported arthritis national estimates. 

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

UAB Researchers Shed Light on Age-Related Osteoporosis

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.